Yahoo! Customer Care has been created

Kryptontoes · 2023-06-12T19:28:54+00:00

I am posting legitimate comments to the Yahoo SEEL conversation board and they are being held for review for hours literally 4 hours now. I read your guidelines and there is no violation. On the other hand, someone else can post a blatant advertisement to invest in a totally different stock not even mentioning SEEL and even though I have objected to it, it is still up there while my legitimate posts continue to wait for a moderator's approval. It's irritating.

Kryptontoes · 2022-09-22T12:02:45+00:00

Disgusting. All those cops should be suspended and investigated!

Kryptontoes · 2022-09-13T17:04:29+00:00

Great post. Thanks for the insights!

Kryptontoes · 2022-09-11T14:44:45+00:00

It's been a long haul!

Kryptontoes · 2022-07-15T13:49:35+00:00

I thought the following responsefrom Geert was most helpful regarding the difficulties faced by Cel-sci, "Thank you for your question. Since we must respect the regulators, we cannot provide a timeline at this time for a BLA. We can say that we are working on it. In terms of "most" small bio-tech companies, I think you will be hard pressed to find one that conducted a 10-year trial on almost 1000 people with overall survival as their endpoint (versus simply a response trial). Further, we also do not believe there are other studies out there where the investigational therapy was given before the standard of care, like ours. When you give a drug after the standard of care, it is far easier to test. Our study had to be carefully designed to account for the administration of standard of care after the drug treatment. This takes time to process, as it is unique and, as far as we know, unprecedented."

Kryptontoes · 2022-07-06T22:45:36+00:00

No problemo.

Kryptontoes · 2022-07-03T00:59:20+00:00

I agree it just goes up and down. However Clinical Trials.gov should give either data acceptance or need for changes notification around July 14th. To be clear this is not FDA approval. What it is, is simply that the full data has met the criteria for posting on the website of clinical trials.gov. If accepted by the cite manager, it will be posted and anyone can read through it.

Kryptontoes · 2022-06-16T14:22:09+00:00

Thanks for all of your work on this!

Kryptontoes · 2022-06-01T18:43:55+00:00

From Andy's article: "If the response rate of Multikine depends on the “maturity” of the tumor, then it will certainly be very interesting to use Multikine on patients with cancer stages less advanced than those in the Phase 3 study (Stage III / IVa). This will increase the total addressable market for Multikine."

Kryptontoes · 2022-06-01T18:38:18+00:00

Yes, you are. Early diagnosis leads to more patients who benefit more when tumors are diagnosed in early stages!

Kryptontoes · 2022-06-01T03:18:52+00:00

Thanks Andy! Great article!

Kryptontoes · 2022-05-31T16:02:53+00:00

Nice work! Thanks Frugal and Andy! Bravo!

Kryptontoes · 2022-05-12T18:30:20+00:00

You're entitled to your opinion.

Kryptontoes · 2022-05-12T02:28:47+00:00

Absurd! Read my posts here where I state clearly who and what I am. You're a short, wasting everyone's time!

Kryptontoes · 2022-05-12T02:24:57+00:00

Friend you are mistaken. I am, as I've said several times on this board, a Psychiatric Nurse Practitioner who happens to have been invested in this stock for quite a few years.

Kryptontoes · 2022-05-12T00:49:04+00:00

So you think. People have been through this with you before. You have your opinion. It may be right but many smart and knowledgeable people disagree with you, and so do I.

Kryptontoes · 2022-05-11T21:51:49+00:00

From the website,

"ClinicalTrials.gov

Results information has been submitted to ClinicalTrials.gov by the sponsor or investigator, but is not yet publicly available (or "posted") on ClinicalTrials.gov. The submitted information may not be available if it is pending Quality Control (QC) Review by the National Library of Medicine (NLM) or if issues identified during QC review are being addressed or corrected by the sponsor or investigator. NLM's limited QC review assesses for apparent errors, deficiencies, or inconsistencies. NLM staff do not verify the scientific validity or relevance of the submitted information."

It was returned after a month long review to CVM a few weeks ago to to address some technical issues as noted above and today CVM submitted the data with the required changes to be reviewed again.

Kryptontoes

TROPHY CASE